The International Federation of Pharmaceutical Manufacturers and Associations asked CRA to review the evidence on the factors increasing access and the associated value of innovation across low and middle income countries for HIV/AIDS from 2000 to 2015. In the report, Tim Wilsdon and Lilian Li present an analysis of access to medicines and the value that these medicines deliver to different countries. The report focuses on six countries that have made progress in providing access to antiretroviral drugs including Botswana, Brazil, China, India, Rwanda, and South Africa and identifies a number of success factors. To read the report, click the link below.
MFN is rewriting the launch planning playbook: Commercial and market access strategies must integrate to succeed
MFN-related uncertainty is reshaping pharmaceutical launch planning by making pricing, sequencing, and forecasting decisions more interconnected and...